Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Exelixis

Explore full profile

Exelixis works on discovering, developing, and commercializing therapies for the treatment of cancer

San Francisco, United StatesFounded 1994Biotech & Life Sciences
Valuation $13B Market cap · Aug/2026
Revenue $2.60B Latest reported FY
EBITDA $1.11B Latest reported FY

At a glance

Status
Listed
Founded
1994
Headquarters
San Francisco, United States
Listing
IPO 2000
Sector
Biotech & Life Sciences
Power Law
Decacorn$10B+ valuation tierThoroughbred$100M+ revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed4 investors entered at this stage

  • PaineWebber
  • Stelios Papadopoulos
  • Atlas Venture
  • Oxford Bioscience Partners

Series A4 investors entered at this stage

  • Hambrecht & Quist Capital Management
  • Domain Associates
  • Pfizer
  • Advent International

Series B and later2 investors entered at this stage

  • University of California
  • Berkeley

Talent

Book a demo to see the people
Employees mapped 1,574 incl. 7 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 10 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 12 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Alumni founders

5 of 12 startups shown

Former Exelixis employees who went on to found companies, sorted by Dealroom signal score.

Quercus BiosolutionsEst. 2024
Jonathan LightnerUnited States
Signal score95
Ventyx BiosciencesEst. 2018
Raju MohanUnited States
Signal score95
Xaira TherapeuticsEst. 2023
Marc Tessier-LavigneUnited States
Signal score92
Grove BiopharmaEst. 2020
Geoffrey M. Duyk, M.D., Ph.D.United States
Signal score90
MiraEst. 2015
SKSylvia KangUnited States
Signal score87
7 more alumni-founded companies in this previewBook a demo

Global footprint

Workforce and web traffic by country
Workforce by country
13 countries with
team presence
🇺🇸 United States98.1%
🇮🇳 India0.5%
🇫🇷 France0.3%
🇧🇩 Bangladesh0.2%
🇺🇦 Ukraine0.1%
Top 5 of 13 shown
Web traffic by country
150K monthly visits
across markets
🇮🇳 India58.4%
🇺🇸 United States13.3%
🇪🇬 Egypt4.5%
🇵🇭 Philippines4.1%
🇧🇩 Bangladesh2.8%
Top 5 markets shown

Patents

Estimated portfolio value
$140M

106 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where Exelixis was the backer or acquirer, 2000–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across Exelixis's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Exelixis's portfolio, mapped.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about Exelixis on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Exelixis on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles